Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study.
Nineteen children (mean [+/- SD] age, 14.5 +/- 2.3 years) with severe, primary obsessive-compulsive disorder completed a ten-week, double-blind, controlled trial of clomipramine hydrochloride (mean dosage, 141 mg/day) or placebo, each of which was administered for five weeks. Half of the subjects had not responded to previous treatment with other tricyclic antidepressants. There was a significant improvement in observed and self-reported obsessions and compulsions that was independent of the presence of depressive symptoms at baseline. Improvement in obsessive-compulsive symptoms did not correlate significantly with plasma concentrations of the drug or its metabolites. Clomipramine appears to be effective in the treatment of children with obsessive-compulsive disorder and the treatment seems to be independent of an antidepressant effect.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D002997:Clomipramine / Q000378:metabolism / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D010043:Outcome and Process Assessment, Health Care; D010555:Personality Inventory; D011569:Psychiatric Status Rating Scales
D000929:Antidepressive Agents, Tricyclic; D002997:Clomipramine